ArriVent BioPharma, Inc. (AVBP) vs Candel Therapeutics, Inc. (CADL)
A side-by-side comparison of ArriVent BioPharma, Inc. and Candel Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$14.45HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
CADL
Candel Therapeutics, Inc.
$9.93HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — AVBP vs CADL
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)CADL +711.9% (+101.0%/yr)CADL compounded faster over this window
Log scale — wide-divergence pair
AVBP CADL
AVBP vs CADL: by the numbers
- •CADL is the larger company ($728M vs $673M market cap).
Metrics side by side
Valuation
| Metric | AVBP | CADL |
|---|---|---|
| P/B ratio | 1.83 | 5.77 |
Profitability
| Metric | AVBP | CADL |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -70.19% |
| ROIC | -47.96% | -36.83% |
Growth (annualized)
| Metric | AVBP | CADL |
|---|---|---|
| Total return CAGR (5Y) | N/A | -1.42% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.